Kyverna abandons next-gen autoimmune CAR-T once touted as follow-up to miv-cel

Kyverna is halting work on a next-gen CD19 CAR-T therapy as the biotech seeks FDA approval for what could become the first CAR-T treatment for an autoimmune disease.